GEHC Q2 Deep Dive: Product Innovation and Service Strength Propel Growth Amid PCS Challenges

Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 5.8% year on year to $5.30 billion. Its non-GAAP profit of $1.13 per share was 9.1% above analysts’ consensus estimates.

Is now the time to buy GEHC? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

GE HealthCare delivered a positive second quarter, with revenue and non-GAAP profit both surpassing Wall Street’s expectations. The company’s performance was driven primarily by robust orders growth, especially in Pharmaceutical Diagnostics and Advanced Imaging Solutions. CEO Peter Arduini credited broad-based demand for GE HealthCare’s portfolio and highlighted the impact of new product launches and improvements in service businesses. The management team acknowledged ongoing challenges in Patient Care Solutions (PCS), noting operational fulfillment issues but emphasizing recent order momentum and ongoing improvement initiatives.

Looking ahead, GE HealthCare’s forward guidance is shaped by strong end-market demand, continued execution of its innovation pipeline, and stabilization efforts within PCS. Management pointed to the ramp-up of new products—particularly in imaging and diagnostics—and further expansion of recurring service revenues as essential to sustaining growth. Arduini stated, “We remain focused on accelerating recovery in PCS and building on the momentum in our innovation pipeline, which we believe will translate into improved revenue and margin through the balance of the year.”

Key Insights from Management’s Remarks

Management attributed the quarter’s results to growth in core product lines, the impact of new innovations, and expanding recurring revenue from service businesses, while highlighting PCS as a continued area for operational improvement.

• Strong orders and backlog: Orders rose 11% year-over-year, with the backlog reaching a record $23.9 billion. Management cited broad-based demand across imaging, diagnostics, and monitoring products, with six new enterprise accounts contributing to growth. The book-to-bill ratio of 1.15x signals potential future revenue strength.

• Service and subscription traction: The recurring revenue base expanded, driven by growth in service contracts and new subscription-based offerings. CEO Arduini emphasized that innovations—like deep learning CT software upgrades—are increasingly offered as subscriptions, supporting a more predictable revenue mix.

• Pharmaceutical Diagnostics momentum: The Pharmaceutical Diagnostics segment posted robust growth, led by increased adoption of advanced imaging agents, such as Vizamyl for Alzheimer’s diagnosis, and the ramp-up of Flyrcado. Management confirmed progress toward the 2028 $500 million annual revenue target for Flyrcado.

• PCS challenges and review: Patient Care Solutions faced operational fulfillment headwinds, resulting in a year-over-year revenue decline. However, strong orders growth in monitoring and anesthesia products was noted. The business is undergoing a strategic review, with options ranging from continued ownership to divestiture being explored.

• AI and operational improvements: Management highlighted the implementation of “Heartbeat,” a business system designed to improve product development and sales execution. The company is also leveraging artificial intelligence both in customer-facing products and internal operations to enhance productivity and margin over time.

Drivers of Future Performance

GE HealthCare’s outlook is anchored by continued innovation, stabilization in PCS, and rising demand for diagnostic and imaging solutions.

• PCS stabilization and margin recovery: Management expects operational improvements in supply chain and manufacturing to drive sequential recovery in PCS revenue and margin in the second half of the year. The team is focusing on backlog conversion and increased shipment velocity, with FDA clearance for premium anesthesia devices anticipated later in 2026.

• Innovation pipeline and product launches: The company’s new wave of imaging, diagnostic, and monitoring products—many featuring artificial intelligence capabilities—are projected to drive growth and higher gross margins. Notably, upcoming launches like Photonova Spectra (photon-counting CT) and ongoing expansion of radiopharmaceuticals are expected to support both revenue and profitability.

• Cost and pricing discipline amid inflation: While inflationary pressures on memory chips and freight remain, management is pursuing price increases and cost actions to offset headwinds. The company expects these measures, together with operational discipline, will help sustain margin expansion through 2027 even as investments in innovation continue.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) the pace of PCS revenue and margin recovery as operational changes take effect; (2) adoption rates and revenue contribution from new imaging and diagnostic product launches, including Photonova Spectra and Flyrcado; and (3) execution of price and cost measures to offset inflation. Progress in the PCS strategic review and service contract growth will also be important to watch.

GE HealthCare currently trades at $71.75, up from $64.11 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.